1. Home
  2. AXIL vs GLTO Comparison

AXIL vs GLTO Comparison

Compare AXIL & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AXIL Brands Inc.

AXIL

AXIL Brands Inc.

HOLD

Current Price

$6.80

Market Cap

46.1M

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$23.07

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXIL
GLTO
Founded
2015
2011
Country
United States
Denmark
Employees
10
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.1M
54.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
AXIL
GLTO
Price
$6.80
$23.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
1.5M
112.3K
Earning Date
01-06-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$27,262,468.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$46.73
N/A
Revenue Growth
0.07
N/A
52 Week Low
$3.75
$2.01
52 Week High
$10.75
$38.33

Technical Indicators

Market Signals
Indicator
AXIL
GLTO
Relative Strength Index (RSI) 50.70 46.54
Support Level $6.55 $21.56
Resistance Level $7.85 $38.33
Average True Range (ATR) 0.86 4.26
MACD -0.14 -1.05
Stochastic Oscillator 7.61 9.01

Price Performance

Historical Comparison
AXIL
GLTO

About AXIL AXIL Brands Inc.

AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, and outdoor speakers, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering. The company operates two operating segments: hearing enhancement and protection, and hair and skin care.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: